Geriatric Pharmacotherapy

Geriatric pharmacotherapy is the specialized field of medication management for older adults, a practice that grows more critical as populations age globally. It’s not merely about prescribing drugs; it’s about navigating the complex interplay between aging physiology, multiple chronic conditions, and an ever-expanding medication list. Mastering this discipline is essential for optimizing therapeutic outcomes while minimizing significant risks like dangerous side effects, hospitalizations, and diminished quality of life.

The Core Challenge: Polypharmacy and Adverse Drug Reactions

Polypharmacy, typically defined as the concurrent use of five or more medications, is exceedingly common in older adults. While often necessary to manage multiple chronic diseases, it is the single greatest risk factor for adverse drug reactions (ADRs). The risk of an ADR increases exponentially with the number of medications taken, not linearly. This is due to complex drug-drug and drug-disease interactions that are harder to predict with each added agent.

For example, consider an 80-year-old patient with heart failure, osteoarthritis, and insomnia. Their regimen might include a diuretic, a beta-blocker, an NSAID for pain, and a sedative-hypnotic for sleep. The NSAID can cause fluid retention, worsening the heart failure and counteracting the diuretic, while the sedative can increase the risk of falls and confusion. This scenario underscores why polypharmacy demands vigilant management rather than passive acceptance. The cornerstone of managing this risk is a regular medication review, a structured, patient-centered process of evaluating all prescribed and over-the-counter medications to ensure each is appropriate, effective, and safe.

Age-Related Pharmacokinetic and Pharmacodynamic Changes

Aging alters how the body handles and responds to drugs, a concept divided into pharmacokinetics (what the body does to the drug) and pharmacodynamics (what the drug does to the body). Ignoring these changes leads to predictable toxicity.

Key pharmacokinetic changes include:

• Absorption: While generally less affected, reduced blood flow can alter the rate of absorption for some drugs.
• Distribution: Increased body fat and decreased total body water change drug distribution. Water-soluble drugs (e.g., digoxin) achieve higher concentrations, while fat-soluble drugs (e.g., diazepam) have longer half-lives.
• Metabolism: Liver mass and blood flow decrease, reducing the clearance of many drugs metabolized by the liver, like certain statins and pain medications.
• Elimination: Declining kidney function is the most clinically significant change. Reduced renal clearance means drugs like certain antibiotics, diabetes medications (e.g., metformin), and cardiovascular agents accumulate, raising the risk of toxicity. Dosing must often be adjusted based on estimated renal function.

Pharmacodynamically, older adults often have increased sensitivity to medications. They may experience a greater therapeutic effect or, more dangerously, a more pronounced adverse effect from a standard dose. For instance, the brain becomes more sensitive to the sedating and deliriant effects of benzodiazepines and anticholinergic drugs, making lower doses imperative.

The Beers Criteria: A Guide to Potentially Inappropriate Medications

To aid clinicians, expert panels have developed tools to identify high-risk medications. The most widely recognized is the Beers Criteria, a list of potentially inappropriate medications (PIMs) for older adults. It highlights drugs that should generally be avoided in this population because their risks often outweigh their benefits, or because safer alternatives exist.

The Beers Criteria is not a strict prohibition list but a critical decision-support tool. It categorizes medications by the strength of the recommendation and the quality of the evidence. Common examples include:

• Anticholinergic drugs (e.g., diphenhydramine, oxybutynin): High risk of confusion, dry mouth, constipation, and urinary retention.
• Benzodiazepines (e.g., diazepam, alprazolam): Increase fall risk, cause sedation, and are associated with dependence.
• Non-steroidal anti-inflammatory drugs (NSAIDs):
• Increase risk of peptic ulcers, kidney injury, and hypertension.
• Certain diabetes drugs (e.g., glyburide): High risk of prolonged, dangerous hypoglycemia.

Using the Beers Criteria during medication review is a proactive strategy to deprescribe harmful agents and prevent new inappropriate prescriptions.

The Solution: Systematic Deprescribing

Deprescribing is the planned and supervised process of dose reduction or stopping of medications that are either no longer beneficial or are causing harm. It is a fundamental skill in geriatric pharmacotherapy and is the logical answer to problematic polypharmacy. A systematic deprescribing protocol involves several key steps:

1. Create a Comprehensive Medication List: Include all prescription, over-the-counter, and herbal products.
2. Identify Potentially Inappropriate Medications: Use tools like the Beers Criteria and consider the patient’s goals of care and life expectancy.
3. Determine if the Medication Can be Deprescribed: Assess the original indication, current benefit, and treatment duration.
4. Plan the Deprescribing Process: Decide whether to stop abruptly or taper gradually, and plan monitoring for discontinuation symptoms or return of the original disease.
5. Monitor, Document, and Provide Follow-Up: Schedule follow-up to confirm the patient’s condition remains stable or improves.

For instance, deprescribing a proton-pump inhibitor prescribed years ago for a healed ulcer, or tapering off a benzodiazepine used for sleep, can significantly improve outcomes by reducing fall risk, clearing confusion, and simplifying the medication regimen without compromising health.

Common Pitfalls

1. Treating Normal Aging with Medication: Mistaking fatigue or mild memory changes for a disease requiring drug therapy can start an unnecessary treatment cascade. First, consider non-pharmacological interventions and rule out other causes like depression or sleep apnea.
2. Ignoring the Anticholinergic Burden: Focusing on one medication in isolation misses the cumulative effect of multiple drugs with anticholinergic properties (e.g., a bladder drug, an antidepressant, and an over-the-counter sleep aid). This total burden strongly predicts cognitive decline and falls.
3. "Prescribing Cascades": This occurs when a new drug is prescribed to treat an adverse effect of an existing drug, mistakenly identified as a new medical condition. A classic example is prescribing an antipsychotic for hallucinations caused by an anticholinergic drug, rather than stopping the offending agent.
4. Skipping the Medication Review: Assuming a long-standing medication list is still optimal is dangerous. Clinical status, organ function, and goals of care change. An annual or bi-annual structured review is a minimum standard for safe geriatric care.

Summary

• Polypharmacy is a major driver of adverse drug reactions in older adults and necessitates regular, comprehensive medication review.
• Age-related changes in pharmacokinetics (especially reduced renal clearance) and increased pharmacodynamic sensitivity mandate careful dose selection and vigilant monitoring.
• The Beers Criteria is an essential evidence-based tool for identifying potentially inappropriate medications that often pose more risk than benefit to elderly patients.
• Deprescribing is a systematic, patient-centered process to reduce medication burden. Following a clear deprescribing protocol is key to safely stopping unnecessary drugs and can significantly improve patient outcomes.
• Successful geriatric pharmacotherapy requires a proactive, skeptical approach to every medication, with a constant focus on balancing benefit, harm, and the patient’s individual health priorities.